

DEMOCRATIC BIG GOVERNMENT PRICE CONTROLS WILL CRUSH BIOMEDICAL INNOVATION & PREVENT FUTURE CURES

The Schumer plan is simply government-run price-controls paired with [sky-high taxes](#) on innovators who save lives. This plan will decrease innovation and prevent future treatments for Americans from being developed. University of Chicago economists estimate the plan will result in [135 fewer new drugs](#), leading to 331.5 million life years lost in the U.S., over the next 17 years.

Despite these projections, Democrats have not answered the question: *Which diseases don't Democrats want to cure?*

Threatening drug discovery and development: Ground-breaking treatments and cures are the products of years-long investment into cutting-edge scientific discovery, rigorous clinical trials, and demanding regulatory review. Under this system, Americans usually have the fastest access to the highest-quality treatments, [often before government-run health care systems](#). These investments, however, are extremely risky:

- On average, it takes [10.5 years](#) from initial research to approval, taking more than a decade for investors to begin earning a return on their investment.
- Many potential drugs in pre-clinical development will never reach a patient, costing manufacturers [\\$474 million](#) in pre-clinical expenses per approval.
- Of those drugs that make it to clinical trials, [nearly 9 out of 10](#) will ultimately fail.
- From 2009 to 2018, the average total cost of developing a new drug was estimated to be nearly [\\$1.4 billion](#), and certain cancer drugs are estimated to cost nearly [\\$4.5 billion](#).

Chilling long-term investment: Democrats' government price-setting would curb investments in drug development – leading to fewer novel medicines reaching patients. Pharmaceutical manufacturers invested more than [\\$120 billion](#) in 2021 in research and development, an average of 25% [of their net revenues](#). These investments, while costly, have developed cures for diseases like [hepatitis C](#), [vaccines](#) against some of the most deadly diseases in human history, and [immunotherapies](#) that are revolutionizing care for cancer patients. On the horizon are innovations that offer hope to patients suffering from debilitating and life-threatening conditions like [sickle cell disease](#), [heart disease](#), and neurological conditions like Alzheimer's disease, [Parkinson's disease](#), and [multiple sclerosis](#).

Generic and biosimilar medicines at-risk: The Democrats' proposal will [decimate development](#) of generic and biosimilar medicines, which are generic versions of biologic drugs, like insulin. Biosimilar medications have the potential to save patients and the health care system [\\$40 billion through 2026](#) alone – exceeding by [eight times](#) the projected savings from the Democrats' "negotiation" scheme over the same period.

Biosimilar development is also an expensive endeavor, costing [\\$100 to \\$200 million](#) to bring a biosimilar to market. Undermining the incentives to develop these medicines means patients may never experience the benefits of the [biosimilar pipeline](#), which includes at least 26 TNF blockers (immunotherapies), 16 cancer medicines, and seven biosimilar insulins, among numerous others. The Democrats' reckless price-control scheme will cause patients to pay more for fewer choices.